Jeremy S Abramson, MD, MMSc, and John P Leonard, MD, debated whether CAR T-cell therapies will have a major impact on outcomes for patients with recurrent DLBCL over the next 3 years.

Blog

While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.

Conferences

Three studies presented at the ASH Annual Meeting and Exposition highlight the emerging role CAR T-cell therapies have in treating certain types of aggressive, refractory blood cancers.

News

Jeremy S Abramson, MD, MMSc, and John P Leonard, MD, debated whether CAR T-cell therapies will have a major impact on outcomes for patients with recurrent DLBCL over the next 3 years.
A global study showed durable remission with long-term persistence in pediatric and young adults with relapsed or refractory B-cell ALL after a single infusion of a CAR T-cell therapy.
Results of a long-term follow-up study show that CAR-T therapy in adults with acute lymphoblastic leukemia may produce durable responses, especially in those with low disease burden.
A recent study attempted to identify genetic biomarkers for patients with chronic lymphocytic leukemia at diagnosis who exhibit indolent disease.

Research in Review

Researchers report significantly improved response rates in patients with CLL treated with concurrent targeted therapy and CAR-T therapy.
Pembrolizumab improves response to chimeric antigen receptor T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia.
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and CAR T-cell therapy tend to have high serum levels of a particular protein.
The authors review the foundational research in CAR-T therapy.
Subscribe to CAR-T Therapies